Pancreatic Cancer News
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.
A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
The NALIRIFOX chemotherapy regimen includes liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.